Ipsogen has launched MapQuant Dx HER2 test. Developed on the MapQuant Dx microarray diagnostic platform, MapQuant Dx HER2 measures a set of HER2-amplified genes that correlate with HER2 protein expression. This new HER2 test provides reliable, intelligible and decisive information for pathologists, oncologists and patients.
Epredia was established in July 2019 through the acquisition by PHC Group of the Anatomical Pathology division of Thermo Fisher Scientific. Our name has changed, however as a standalone business our mission remains the same: to improve lives by enhancing cancer diagnostics.
We are powered by the quality brands you know and trust, such as...
Hyatt Regency, Orlando, FL
3-5 November, 2025
America Square Conference Centre, London, EC3N 2LB.
4 - 5 November, 2024
Messe Dusseldorf
11-14 November, 2024
SEC Arena, Glasgow
14 November, 2024
Hyatt Regency, Vancouver, Canada
19-23 November, 2024
